LIVE WEBINAR: Thursday, June 23, 2022, 5:00 PM – 6:00 PM Eastern Time (ET)

PARP Inhibition in the Management of Prostate Cancer — Where We Are and Where We’re Headed

A CME/MOC-Accredited Virtual Event

Register Now

Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.


Join us on Thursday, June 23rd for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Faculty
Johann S de Bono, MB ChB, MSc, PhD, FMedSci
Regius Professor of Cancer Research
Professor of Experimental Cancer Medicine and Honorary Consultant in Medical Oncology
Head of Clinical Studies Division
Director of Drug Development Unit
Head of the Prostate Cancer Targeted Therapy Group
The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust
London, United Kingdom

Additional faculty to be announced.

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Merck.

Thursday, June 23, 2022
5:00 PM – 6:00 PM Eastern Time
Live CME/MOC-accredited webinar

Topics to Be Discussed

  • Activity, tolerability and mechanistic similarities and differences among approved and investigational PARP inhibitors for metastatic castration-resistant prostate cancer
  • Optimal management of toxicities associated with PARP inhibitors in patients with prostate cancer
  • Available data with PARP inhibitors in combination with secondary hormonal therapy
  • Evaluation of PARP inhibitors and androgen receptor-targeted therapy in earlier treatment settings; ongoing Phase III studies in metastatic hormone-sensitive disease

Target Audience
This activity is intended for medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Recognize the frequency of BRCA1/2 and other homologous recombination repair (HRR) mutations in patients with prostate cancer, and develop a rational clinical algorithm to guide the use of genetic testing.
  • Assess the pharmacologic, pharmacodynamic and pharmacokinetic similarities and differences among the approved and investigational PARP inhibitors for prostate cancer to better understand the activity and toxicities of these agents.
  • Explore the available research database supporting the use of PARP inhibitor monotherapy for patients with metastatic castration-resistant prostate cancer, and discern how to optimally incorporate these agents into clinical management algorithms.
  • Understand the rationale for, available and emerging data with and ongoing research evaluating PARP inhibitors in combination with androgen receptor-targeted therapy, and consider the potential role of these novel regimens for patients with and without HRR gene mutations.
  • Recognize the side effects associated with PARP inhibitors for prostate cancer, and develop strategies to prevent, mitigate and manage toxicities.

CE Credit
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Merck.